Oncology · Phase I

Top sponsors

• Chinese Academy of 70 programs
• First People's Hospital 62 programs
• Takeda 49 programs
• United Therapeutics Europe 41 programs
• BEONE MEDICINES AUS 40 programs
• Regeneron UK 34 programs
• Anaxis Pharma 31 programs
• Chongqing Precision Biotech 27 programs
• Janssen-Cilag International N.V 27 programs
• Novartis India 27 programs
• Boehringer Ingelheim 24 programs
• BRIGHT MINDS BIOSCIENCES 23 programs

1. 0439-24

   Lacuna Pharma Pty Ltd

   Melanoma

   phase 1 · other · active

   1 trial →

2. 1 mg/kg GR-MD-02

   GALECTIN THERAPEUTICS INC

   Metastatic Melanoma

   phase 1 · mab · completed

   1 trial →

3. 1230.15

   Boehringer Ingelheim

   Neoplasms

   phase 1 · small molecule · completed

   1 trial →

4. 1403-0001

   Boehringer Ingelheim

   Advanced or metastatic solid tumors

   phase 1 · other · active

   1 trial →

5. 1403-0002

   Boehringer Ingelheim

   advanced solid tumors

   phase 1 · other · active

   1 trial →

6. 1403-0004

   Boehringer Ingelheim

   Solid cancer tumors

   phase 1 · other · active

   1 trial →

7. 1438-0001

   Boehringer Ingelheim

   Small Cell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

   phase 1 · other · active

   1 trial →

8. 1438-0007

   Boehringer Ingelheim

   Extra-pulmonary neuroendocrine carcinoma (epNEC), Neuroendocrine carcinoma (NEC) with unknown primary site, pulmonary Large cell neuroendocrine carcinoma (LCNEC)

   phase 1 · other · active

   1 trial →

9. 1438-0008

   Boehringer Ingelheim

   Extensive-stage small cell lung carcinoma (ES-SCLC)

   phase 1 · other · active

   1 trial →

10. 1438-0009

    Boehringer Ingelheim

    relapsed/refractory extensive stage - small cell lung cancer (ES-SCLC)

    phase 1 · other · active

    1 trial →

11. 1443-0002

    Boehringer Ingelheim

    head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma

    phase 1 · other · active

    1 trial →

12. 1443-0003

    Boehringer Ingelheim

    non-small cell lung cancer or, melanoma, head and neck squamous cell carcinoma

    phase 1 · other · active

    1 trial →

13. 145 mg/m2 NKTR 102

    Nektar Therapeutics UK Limited

    Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment

    phase 1 · small molecule · completed

    1 trial →

14. 1454-0015

    Boehringer Ingelheim

    colorectal carcinoma (CRC)

    phase 1 · other · active

    1 trial →

15. 1456-0001

    Boehringer Ingelheim

    solid tumors

    phase 1 · other · active

    1 trial →

16. 1463-0001

    Boehringer Ingelheim

    Advanced head and neck cancer

    phase 1 · other · active

    1 trial →

17. 1479-0001

    Boehringer Ingelheim

    Solid tumours with HER2 aberrations, Non-small cell lung cancer

    phase 1 · other · active

    1 trial →

18. 1501-0002

    Boehringer Ingelheim

    Head and neck squamous cell carcinoma

    phase 1 · other · active

    1 trial →

19. 1505-0001

    Boehringer Ingelheim

    Metastatic pancreatic ductal adenocarcinoma (mPDAC)

    phase 1 · other · active

    1 trial →

20. 1527-0001

    Boehringer Ingelheim

    Melanoma, Solid tumours

    phase 1 · other · active

    1 trial →

21. 1538-0001

    Boehringer Ingelheim

    advanced, unresectable and/or metastatic solid tumors

    phase 1 · other · active

    1 trial →

22. 17651

    Disc Medicine

    Locally advanced rectal cancer

    phase 1 · other · active

    1 trial →

23. 177Lu-DOTA-TLX591

    Telix Innovations

    Metastatic Prostate Cancer

    phase 1 · mab · completed

    1 trial →

24. 177Lu-TLX250 and Peposertib

    Telix Innovations

    Solid Tumor, Adult

    phase 1 · other · active

    1 trial →

25. 18F-FAPIBiotin

    The First People's Hospital of Lianyungang

    Malignant Neoplasm

    phase 1 · small molecule · active

    1 trial →

26. 18F-FDG

    The First People's Hospital of Lianyungang

    Multiple Myeloma and Malignant Plasma Cell Neoplasms

    phase 1 · small molecule · active

    1 trial →

27. 18F-PEG6-IPQA

    United Therapeutics Europe Ltd

    Lung Cancer

    phase 1 · small molecule · completed

    1 trial →

28. 19(T2)28z1xx CAR T cells

    Takeda

    Diffuse Large B Cell Lymphoma

    phase 1 · small molecule · active

    1 trial →

29. 19(T2)28z1xx TRAC T cell

    Takeda

    B-Cell Lymphoma

    phase 1 · mab · active

    1 trial →

30. 20 mg/kg TRU-016 + Rituximab

    Aptevo Therapeutics

    Chronic Lymphocytic Leukemia

    phase 1 · mab · terminated

    1 trial →

31. 2001-0001

    Boehringer Ingelheim

    Advanced relapsed or refractory ovarian cancer, Advanced relapsed or refractory endometrial cancer, Advanced relapsed or refractory germ cell tumours

    phase 1 · other · active

    1 trial →

32. 2012-0001

    Boehringer Ingelheim

    unresectable advanced or metastatic solid cancer

    phase 1 · other · active

    1 trial →

33. 20160323

    Amgen

    Small Cell Lung Cancer

    phase 1 · other · active

    1 trial →

34. 2018-523-00US1

    Hutchmed Europe B.V.

    Lymphoma

    phase 1 · other · active

    1 trial →

35. 20180146

    Amgen

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 1 · other · active

    1 trial →

36. 20190135

    Amgen

    Advanced Solid Tumors Kirsten Rat Sarcoma (KRAS) pG12C Mutation

    phase 1 · other · active

    1 trial →

37. 2020-306-GLOB1

    Hutchmed Europe B.V.

    - Acute myeloid leukemia - Myelodysplastic syndrome/ Myeloproliferative neoplasm - Angio-immunoblastic T-cell lymphoma - Other mIDH-positive hematological malignancies (other than tumor types mentioned above)

    phase 1 · other · active

    1 trial →

38. 20200469

    Amgen

    Extensive Stage Small cell lung cancer (ES-SCLC)

    phase 1 · other · active

    1 trial →

39. 20220028

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 · other · active

    1 trial →

40. 20230167

    Amgen

    Thoracic tumors with homozygous MTAP-deletion

    phase 1 · other · active

    1 trial →

41. 20230223

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 · other · active

    1 trial →

42. 20230237

    Amgen

    Newly diagnosed localized Intermediate or High‐Risk Prostate Cancer

    phase 1 · other · active

    1 trial →

43. 20230298

    Amgen

    Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

    phase 1 · other · active

    1 trial →

44. 20240031

    Amgen

    KRAS Altered Advanced or Metastatic Solid Tumors

    phase 1 · other · active

    1 trial →

45. 20240124

    Amgen

    Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    phase 1 · other · active

    1 trial →

46. 20250004

    Amgen

    microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) solid tumors

    phase 1 · other · active

    1 trial →

47. 20511

    Bayer AG

    Prostate cancer

    phase 1 · other · active

    1 trial →

48. 208850

    GlaxoSmithKline

    Neoplasms

    phase 1 · other · active

    1 trial →

Frequently asked questions